Clinical Trial Update: Study of CB-183,315 in Participants With Clostridium Difficile Infection [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of CB-183,315 in participants with Clostridium difficile infection has completed and results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridium Difficile Infection
• Diarrhea

Drugs mentioned

• CB-183,315

Snippet

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Clostridium Difficile Infection, Diarrhea | Phase 2 | Status: COMPLETED | Results posted: 2015-06-16